文献速递胸部肿瘤

阿替利珠单抗在合并抗生素或质子泵抑制剂治疗的晚期非小细胞肺癌患者中的疗效:五项随机对照试验的汇总分析

Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials.
PubMed 文献 · J Thorac Oncol · 2022-02-17

该研究汇总五项评估阿替利珠单抗治疗晚期非小细胞肺癌的随机对照试验,按随机化时抗生素和质子泵抑制剂使用情况分层分析疗效。抗生素使用者与未使用者的阿替利珠单抗总生存疗效相似(交互作用P=0.35),而质子泵抑制剂使用者的疗效降低(交互作用P=0.003)。质子泵抑制剂使用与治疗前淋巴细胞、CD19+和CD16+CD56+免疫细胞计数降低相关。

要点

  • 抗生素使用者与未使用者的阿替利珠单抗总生存疗效相似(交互作用P=0.35)。
  • 质子泵抑制剂使用者的阿替利珠单抗疗效降低(交互作用P=0.003)。
  • 质子泵抑制剂使用与治疗前淋巴细胞、CD19+和CD16+CD56+免疫细胞计数降低相关。

核心结论

  • 阿替利珠单抗疗效在抗生素使用者中未见差异。
  • 质子泵抑制剂使用 consistently 与阿替利珠单抗疗效降低及治疗前淋巴细胞、CD19+和CD16+CD56+免疫细胞计数降低相关。
  • 鉴于约30%的癌症患者使用质子泵抑制剂,亟需关于质子泵抑制剂对其他免疫检查点抑制剂影响的证据以及免疫检查点抑制剂治疗中非必要质子泵抑制剂使用的指南。

研究设计与样本

  • 汇总五项评估阿替利珠单抗治疗晚期非小细胞肺癌的随机对照试验(IMpower130、IMpower131、IMpower150、OAK和POPLAR)。
  • 共纳入4458例参与者,其中285例在治疗前30天内接受过抗生素,1225例在治疗开始时使用质子泵抑制剂。
  • 按随机化时抗生素和质子泵抑制剂使用情况分层评估阿替利珠单抗疗效(风险比及95%置信区间)。
  • 探索抗生素和质子泵抑制剂使用与治疗前外周血免疫表型的关联。

主要发现

  • 抗生素使用者阿替利珠单抗总生存风险比为0.73(95%CI 0.53-0.99),抗生素未使用者为0.82(95%CI 0.74-0.91),交互作用P=0.35。
  • 质子泵抑制剂使用者阿替利珠单抗总生存风险比为1.00(95%CI 0.85-1.17),质子泵抑制剂未使用者为0.76(95%CI 0.69-0.83),交互作用P=0.003。
  • 上述结果在各随机对照试验间一致,无进展生存期结果亦一致。
  • 质子泵抑制剂使用与淋巴细胞、CD19+和CD16+CD56+免疫细胞计数分别降低9%、18%和9%相关(P<0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Gut dysbiosis may reduce immune checkpoint inhibitor (ICI) efficacy. Antibiotics and proton pump inhibitors (PPIs) are commonly used drugs causing gut dysbiosis. There is limited randomized controlled trial (RCT) evidence on whether antibiotics or PPIs impact ICI benefit versus comparator treatments. METHODS: This study pooled five RCTs (IMpower130, IMpower131, IMpower150, OAK, and POPLAR) evaluating atezolizumab in advanced NSCLC. Atezolizumab efficacy (hazard ratio with 95% confidence intervals) was assessed for subgroups on the basis of antibiotic and PPI use at randomization. The association between antibiotic and PPI use with pretreatment peripheral blood immunophenotype was also explored. RESULTS: Of 4458 participants, 285 received an antibiotic in the 30-day pretreatment and 1225 were using a PPI at treatment initiation. Overall survival efficacy of atezolizumab was similar (p[interaction] = 0.35) for antibiotic users (hazard ratio 95% confidence interval: 0.73 [0.53-0.99]) and antibiotic nonusers (0.82 [0.74-0.91]). Nevertheless, efficacy was reduced (p[interaction] = 0.003) for PPI users (1.00 [0.85-1.17]) compared with PPI nonusers (0.76 [0.69-0.83]). Findings were consistent across RCTs and for progression-free survival. PPI use was associated with 9%, 18%, and 9% lower counts of lymphocytes, CD19+, and CD16+CD56+ immune cells, respectively (p < 0·01). CONCLUSIONS: Reassuringly, atezolizumab efficacy did not differ for antibiotic users. Opposingly, PPI use was consistently associated with decreased atezolizumab efficacy and lower pretreatment counts of lymphocytes, CD19+, and CD16+CD56+ immune cells. Given that approximately 30% of patients with cancer use PPIs, there is an urgent need for evidence on the impacts of PPIs on other ICIs and for the development of guidelines on nonessential PPI use with ICIs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Hopkins AM, Badaoui S, Kichenadasse G, et al. Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials. J Thorac Oncol. 2022. PMID: 35183773. doi:10.1016/j.jtho.2022.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。